Brokerage Firm Rating on Anthera Pharmaceuticals (ANTH)

Anthera Pharmaceuticals (ANTH) : 4 analysts are covering Anthera Pharmaceuticals (ANTH) and their average rating on the stock is 1, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.

Anthera Pharmaceuticals (ANTH) : 4 Wall Street analysts covering Anthera Pharmaceuticals (ANTH) believe that the average level the stock could reach for the short term is $10.75. The maximum price target given is $14 and the minimum target for short term is around $9, hence the standard deviation is calculated at $2.22.


For the current week, the company shares have a recommendation consensus of Buy. Anthera Pharmaceuticals (NASDAQ:ANTH): The stock opened at $3.03 on Thursday but the bulls could not build on the opening and the stock topped out at $3.07 for the day. The stock traded down to $2.99 during the day, due to lack of any buying support eventually closed down at $3.01 with a loss of -0.33% for the day. The stock had closed at $3.02 on the previous day. The total traded volume was 303,251 shares.

In a related news,The (Chief Medical Officer) of Anthera Pharmaceuticals Inc, Hislop Colin sold 12,500 shares at $5.31 on November 13, 2015. The Insider selling transaction had a total value worth of $66,375. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Anthera Pharmaceuticals Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Companys primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others. The Companys second product candidate Sollpura (liprotamase) is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI) often seen in patients with cystic fibrosis and other conditions.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.